Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals, sold 1,291 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Summary

• On January 22, 2025, Jeffrey Eisele, the Chief Development Officer of Apellis Pharmaceuticals, sold 1,291 shares of the company's common stock.
• The sale was executed at a price of $30.4255 per share.
• This transaction was conducted to cover tax withholding obligations associated with Restricted Stock Units that were released on January 21, 2025.
• Following the transaction, Eisele directly owns 55,590 shares of Apellis Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations. It doesn't necessarily reflect a positive or negative view of the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the context.

Key Dates

Keywords

Apellis Pharmaceuticals, Jeffrey Eisele, Form 4, Share Sale, Restricted Stock Units, Tax Withholding, APLS, Insider Trading